| Title | Author(s) | Year | View Count |
 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | Liaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV | 2009 | 1,824 |
 | Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients | Hsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P | 2009 | 301 |
| Presence of Biopsy-Proven Histologic Damage (Necroinflammation And Fibrosis) is Common Even When ALT is Less Than 2X ULN in Patients With Chronic Hepatitis B (CHB) | Nerrault, N; Kim, WR; Lim, SG; Papatheodoridis, G; Alberti, A; Yuen, RMF; Goodman, ZD; Vaughan, J; Wilber, R; Kreter, B | 2007 | 96 |
|
